メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
Keio University ホーム
ヘルプ＆FAQ
English
日本語
ホーム
プロファイル
研究部門
研究成果
専門知識、名前、または所属機関で検索
Scopus著者プロファイル
上蓑 義典
臨床検査医学
ウェブサイト
https://k-ris.keio.ac.jp/html/100006921_ja.html
h-index
2504
被引用数
22
h 指数
Pureの文献数とScopusの被引用数に基づいて算出されます
2013
2026
年別の研究成果
概要
フィンガープリント
ネットワーク
研究成果
(113)
類似のプロファイル
(6)
フィンガープリント
Yoshifumi Uwaminoが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Immunology and Microbiology
Severe Acute Respiratory Syndrome Coronavirus 2
100%
COVID-19
83%
Mycobacterium Avium Complex
75%
Vaccine Efficacy
50%
Vaccination Policy
46%
Adoptive Immunity
37%
Humoral Immunity
34%
Monospecific Antibody
30%
Mycobacteria
30%
Infectious Agent
29%
Minimum Inhibitory Concentration
22%
Hemodialysis
18%
Mycobacterium abscessus
18%
Antibody Titer
17%
Lineages
16%
Morphotype
15%
Booster Dose
15%
Omicron Coronavirus Variant
15%
Enterococcus faecium
14%
Breakthrough Infection
14%
Microbiome
14%
Meningitis
14%
Pseudomonas aeruginosa
13%
Interferon Gamma
12%
Macrophage
12%
Computer Assisted Tomography
12%
Neutralizing Antibody
11%
Mycobacterium Tuberculosis
11%
Prevalence
11%
Receptor Binding
11%
Inflammatory Arthritis
10%
Comorbidity
10%
Viral Disease
10%
Type Strain
10%
Neutralization
10%
Titer
9%
Medical Record
9%
Biosynthesis
9%
Dynamics
9%
Infectious Disease
9%
Large Intestine
9%
Normal Human
9%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
9%
Species Identification
9%
C-Reactive Protein
9%
Viral Load
9%
Vancomycin-Resistant Enterococcus
9%
Aspergillus
9%
Parenchyma
9%
Hemocyte
9%
Medicine and Dentistry
Mycobacterium Avium Complex
78%
COVID-19
70%
Severe Acute Respiratory Syndrome Coronavirus 2
66%
Silo-Filler's Disease
61%
Infection
51%
Disease
49%
COVID-19 Vaccination
30%
Cross Sectional Study
28%
COVID-19 Vaccine
23%
Mycobacteria
21%
Adverse Event
19%
Observational Study
18%
Amikacin
18%
Diethylstilbestrol
18%
Polymerase Chain Reaction
18%
Diagnosis
17%
Booster Dose
14%
Prevalence
13%
Mycobacterium abscessus
12%
Outpatient
12%
Polymerase Chain Reaction
12%
Antibiotic Therapy
12%
Nasopharyngeal Swab
12%
Health Care Cost
12%
Disease Course
11%
Disease Severity
10%
Humoral Immunity
10%
Quality of Life
10%
Gastrointestinal Distress
10%
Combination Therapy
10%
Mycobacterial Infection
10%
Pseudomonas Infection
9%
Sitafloxacin
9%
Vancomycin Resistant Enterococcus
9%
Multiplex Polymerase Chain Reaction
9%
Quantitative Reverse Transcription Polymerase Chain Reaction
9%
University Student
9%
Interstitial Lung Disease
9%
Subclinical Infection
9%
Blood Cell
9%
Antimicrobial Therapy
9%
Vancomycin
9%
C Reactive Protein
9%
Relebactam
9%
Nacubactam
9%
Mastoidectomy
9%
Drug Therapy
9%
Histoplasmosis
9%
Infectious Disease Treatment
9%
Autoantibodies
9%
Keyphrases
Infectious Diseases
18%
Nacubactam
18%
SARS-CoV-2 Infection
12%
Patients with COVID-19
12%
COVID-19
12%
Disease Severity
12%
Nontuberculous Mycobacterial Lung Disease
10%
Rheumatoid Arthritis
10%
Comorbidity
10%
Biosynthetic Pathway
9%
Nontuberculous Mycobacterial Infection
9%
Hsa-miR-346
9%
Viral Burden
9%
Anti-interferon-γ Autoantibody
9%
Colony Morphotype
9%
Mycolicibacterium
9%
Bile Acids
9%
Japanese Society
9%
E484K mutation
9%
Mycobacterium Avium Complex Lung Disease
9%
Monovalent Vaccine
9%
Low Serum
9%
Complete Genome Sequence
9%
Antibacterial Susceptibility
9%
Clinical Microbiology
9%
Commensal Neisseria
9%
Acute Cholangitis
9%
Neisseria Subflava
9%
Rifampicin
9%
Bacterial Respiratory Pathogens
9%
Early Prognostication
9%
Relebactam
9%
Reaction Threshold
9%
Value Cycle
9%
Histoplasmosis
9%
Latent Tuberculosis Infection Treatment
9%
Disseminated Histoplasmosis
9%
14-Hydroxyclarithromycin
9%
Asymptomatic Infection
9%
Mild COVID-19
9%
Media Differences
9%
Pneumonia
9%
Outpatient Parenteral Antibiotic Therapy
9%
Community-acquired
9%
Serum Estradiol Level
9%
Centenarians
9%
3C-like Protease (3CLpro)
9%
Single Center
9%
Testosterone
9%
Sars-cov-2 Infection
9%
